Quy Nhon, July 15, 2024 – Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (Bidiphar), a leader in peritoneal dialysis solutions in Vietnam, is proud to announce the signing of a memorandum of understanding (MOU) with Crearene AG, a Swiss-based company, to develop creatine-based treatment solutions for dialysis patients. This partnership aims to sign a licensing agreement, bringing significant advancements in healthcare for dialysis patients.
Ms. Pham Thi Thanh Huong, General Director of Bidiphar, stated: “Improving the quality of life for dialysis patients has always been our top priority. Through this promising collaboration with Crearene AG, we aim to introduce groundbreaking improvements in dialysis treatment. Scientific research indicates that dialysis patients often suffer from creatine deficiency, leading to fatigue and muscle weakness. By supplementing creatine in the treatment process, we hope to significantly enhance their quality of life.”
Bidiphar prides itself on being a pioneering science and technology enterprise, continuously investing in research and development (R&D) to create high-value pharmaceutical products that meet the growing demands of the market and consumers. The collaboration with Crearene AG, a company with extensive experience and in-depth research on creatine, will enable Bidiphar to further assert its leading position in dialysis treatment in Vietnam.
Crearene AG is a medical technology company based in Switzerland, with a team of researchers and scientists dedicated to developing advanced technologies to improve the quality of life for dialysis patients. Crearene’s solutions promise significant improvements, helping thousands of dialysis patients enhance their health and daily lives.
Dr. Frank Heideloff, CEO of Crearene AG, shared: “Currently, over 3 million dialysis patients worldwide require regular treatment. In some advanced healthcare markets, governments have emphasized the need for increased research efforts to improve dialysis treatment from a patient perspective. We are delighted to partner with Bidiphar to bring innovation to the market, improving the physical condition and overall health of the increasing number of dialysis patients. Crearene’s patented technology, resulting from years of research on the use of creatine, combined with Bidiphar’s superior production capabilities and market understanding in Vietnam, provides an excellent basis for this endeavor.”
Over the past year, Bidiphar and Crearene have worked together to gather information and conduct necessary research. Following this MOU, Bidiphar’s research center will continue to work closely with Crearene to move towards a licensing agreement in Vietnam. Bidiphar will be the first company in Vietnam and the region to have this technology.
The combination of Crearene’s patented technology and Bidiphar’s production and market access capabilities in the Vietnamese medical sector is a solid foundation to bring effective treatment solutions, improving the health and well-being of dialysis patients. Bidiphar is committed to continuing its investment in R&D, continuously improving the quality of products and services to bring the best value to the community.
